Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY25 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.70, $0.38 better than the analyst estimate of $0.32. Revenue for the quarter came in at $141.8 million versus the consensus estimate of $133.68 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $558 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- Enablence closes C$25M private placement with Collingwood Investments
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
